Pregnant women, with gestational age at inclusion <28 weeks of amenorrhea, with or without risk factors for GDM will be included in the first consultation at the Maternity Hospital (Bordeaux University Hospital).

Determination of glycation markers (HbA1c, glycated albumin, and skin autofluorescence).

Gestational Diabetes Mellitus increases the risk of adverse pregnancy outcomes (such as macrosomia).

The lack of early clinical symptoms leads to screen pregnant women for GDM, and the strategies of screening are a matter of debate.

Interventions to control glucose levels in women with GDM have demonstrated efficacy in terms of macrosomia. However, macrosomia may start before the time of screening, suggesting that markers of glycation may have interest : skin autofluorescence, glycated albumin.

The primary outcome is the incidence of GDM diagnosed during pregnancy after inclusion in the trial. The measure is performed by fasting blood glucose:≥ 0.92 g/L and < 1.26 g/L,or based on the result of the 75g OGTT performed at 24-28 weeks of amenorrhea, if glycemia at time 0 ≥ 92 mg/dL (5.06 mmol/L) and/or time 60min ≥ 180 mg/dL (9.9 mmol/L) and/or time 120min ≥153 mg/dL (8.42 mmol/L).

Incidence of fetal death in utero

Incidence of labor induction, caesarean section, instrumental delivery.